A
Alberto Margonato
Researcher at Vita-Salute San Raffaele University
Publications - 281
Citations - 6866
Alberto Margonato is an academic researcher from Vita-Salute San Raffaele University. The author has contributed to research in topics: Heart failure & Coronary artery disease. The author has an hindex of 36, co-authored 266 publications receiving 6009 citations. Previous affiliations of Alberto Margonato include University of Milan & Università telematica San Raffaele.
Papers
More filters
Journal ArticleDOI
Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease.
Francesco Montorsi,Alberto Briganti,Andrea Salonia,Patrizio Rigatti,Alberto Margonato,Andrea Macchi,Stefano Galli,Paolo Ravagnani,Piero Montorsi +8 more
TL;DR: It is suggested that a significant proportion of patients with angiographically documented coronary artery disease have erectile dysfunction and that this latter condition may become evident prior to angina symptoms in almost 70% of cases.
Journal ArticleDOI
“Ultrasound Comet-Tail Images”: A Marker Of Pulmonary Edema: A Comparative Study With Wedge Pressure And Extravascular Lung Water
Eustachio Agricola,Tiziana Bove,Michele Oppizzi,Giovanni Marino,Alberto Zangrillo,Alberto Margonato,Eugenio Picano +6 more
TL;DR: The presence and the number of comet-tail images provide reliable information on interstitial pulmonary edema, and ultrasonography represent an attractive, easy-to-use, bedside diagnostic tool for assessing cardiac function and pulmonary congestion.
Journal ArticleDOI
A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure.
Gabriele Fragasso,Altin Palloshi,Patrizia Puccetti,Carmen Silipigni,Alessandra Rossodivita,Mariagrazia Pala,Giliola Calori,Ottavio Alfieri,Alberto Margonato +8 more
TL;DR: Long-term trimetazidine improves functional class and left ventricular function in patients with HF, which contrasts with the natural history of the disease, as shown by the decrease of EF in patients on standard HF therapy alone.
Journal ArticleDOI
Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure.
Gabriele Fragasso,Gianluca Perseghin,Francesco De Cobelli,Antonio Esposito,Altin Palloshi,Guido Lattuada,Paola Scifo,Giliola Calori,Alessandro Del Maschio,Alberto Margonato +9 more
TL;DR: Timetazidine improves functional class and LV function in patients with heart failure and is associated to the observed trimetazidine-induced increase in the PCr/ATP ratio, indicating preservation of the myocardial high-energy phosphate levels.
Journal ArticleDOI
Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy.
Gabriele Fragasso,P. M. Piatti,Lucilla D. Monti,Altin Palloshi,Emanuela Setola,P Puccetti,Giliola Calori,Gary D. Lopaschuk,Alberto Margonato +8 more
TL;DR: In a short series of patients with diabetes and ischemic cardiomyopathy, TMZ improved left ventricular function, symptoms, glucose metabolism, and endothelial function, and shifting energy substrate preference away from fatty acid metabolism and toward glucose metabolism by TMZ appears an effective adjunctive treatment.